Vorolanib - Tyrogenex

Drug Profile

Vorolanib - Tyrogenex

Alternative Names: CM-082; X-82

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tyrogenex
  • Developer AnewPharma; Tyrogenex; Washington University School of Medicine
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Platelet-derived growth factor beta receptor antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Renal cell carcinoma
  • Phase II Age-related macular degeneration
  • Phase I/II Pancreatic cancer
  • Phase I Solid tumours

Most Recent Events

  • 15 Sep 2017 AnewPharma plans a phase I trial for Gastric cancer (Late-stage disease, Combination therapy, Second-line therapy or greater) in China (PO) (NCT03286244)
  • 08 Jun 2017 Adverse events data from a phase I/II trial in Age-related macular degeneration released by Tyrogenex
  • 02 Jun 2017 Phase-II/III clinical trials in Renal cell carcinoma (Combination therapy, Metastatic disease, Second-line therapy or greater, Late-stage disease) in China (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top